MYC and endometrial cancer: Additionally, a DAXX-inhibition strategy offers an opportunity for other PTEN-null tumours where MYC and CYCLIN-D1 are upregulated, including medulloblastomas, endometrial cancer, breast cancer and melanoma8, 46, 47.